Empowering the inventor - The case of monoclonal antibodies

Nature Biotechnology

Volumn 23, Issue 9, 2005, Pages 1047-1049

  Clark, Mike ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTELLECTUAL PROPERTY;

ACADEMIC OWNERSHIPS; COMMERCIALIZATION;

MONOCLONAL ANTIBODIES;

ALEMTUZUMAB; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

B CELL LEUKEMIA; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HUMAN; IMMUNOGENICITY; LEGAL ASPECT; LICENCE; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; PUBLICATION; SHORT SURVEY; UNIVERSITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL SCIENCES; BIOTECHNOLOGY; HUMANS; INFORMATION DISSEMINATION; INTELLECTUAL PROPERTY; PATENTS; RESEARCH SUPPORT; TECHNOLOGY TRANSFER;

EID: 27144538072     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0905-1047     Document Type: Short Survey

References (6)

1. Kohler, G. & Milstein, C. Nature 256, 495-497 (1975).
2. Milstein, C. Immunol. Today 21, 359-364 (2000).
3. Hale, G. & Waldmann, H. Methods Mol. Med. 40, 243-266 (2000).
4. Cambridge University. Third Joint Report of the Council and the General Board on the Ownership of Intellectual Property Rights (IPRs): Notice. Cambridge University Reporter, 6008, 3. (Cambridge University, UK, 2005).
5. Lambert, R. Lambert Review of Business-University Collaboration (Her Majesty's Stationary Office, Norwich, UK, 2003). http://www.hm-treasury.gov.uk./ media/DDE/65/lambert_review_final_450.pdf
6. http://www.erbi.co.uk/